Compare NXDT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | BDSX |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.8M | 276.2M |
| IPO Year | 2006 | 2020 |
| Metric | NXDT | BDSX |
|---|---|---|
| Price | $3.14 | $7.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.17 |
| AVG Volume (30 Days) | 220.3K | ★ 270.6K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $85,965,000.00 | ★ $88,499,000.00 |
| Revenue This Year | N/A | $18.90 |
| Revenue Next Year | N/A | $20.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.30 | ★ 24.08 |
| 52 Week Low | $2.61 | $5.26 |
| 52 Week High | $5.95 | $31.97 |
| Indicator | NXDT | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 30.60 | 20.77 |
| Support Level | N/A | N/A |
| Resistance Level | $5.49 | $16.66 |
| Average True Range (ATR) | 0.25 | 1.73 |
| MACD | 0.00 | -0.45 |
| Stochastic Oscillator | 26.61 | 0.00 |
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.